| Trial ID: | L0007 |
| Source ID: | NCT01817322
|
| Associated Drug: |
Standard Dose Of Myfortic And Reduced Dose Of Myfortic
|
| Title: |
Kidney Graft Function Under the Immunosuppression Strategies
|
| Acronym: |
MyLowCsA
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Renal Disease
|
| Interventions: |
DRUG: Standard Dose of Myfortic and Reduced Dose of Myfortic|DRUG: Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental group|DRUG: Basiliximab injected both control group and experimental group
|
| Outcome Measures: |
Primary: eGFR (abbreviated MDRD equation), Primary objective: To compare the renal function with eGFR (abbreviated MDRD equation) 6 months after transplantation, 6 months after transplantation | Secondary: safety, graft survival and patient survival, 6 months after transplantation
|
| Sponsor/Collaborators: |
Sponsor: Samsung Medical Center
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
140
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2011-06
|
| Completion Date: |
2013-08
|
| Results First Posted: |
|
| Last Update Posted: |
2014-10-03
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT01817322
|
